Diabetes Combination Studies Leave Market Challenges Unresolved
Executive Summary
Novo Nordisk and Sanofi's trials were intended to satisfy FDA's combination product rule, but sponsors have not addressed some important clinical questions around use of the basal insulin/GLP-1 agonist products.
You may also be interested in...
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.